Physician profile
Jeffrey Greco
NPI 1770667388
$12,890.83
in general payments reported to CMS, 2019-2025
40 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,059 · 2020: $1,671 · 2021: $2,209 · 2022: $2,089 · 2023: $2,177 · 2024: $1,654 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.62 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,098.85 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $2,065.15 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,159.96 | 2019-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $1,136.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $1,091.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,032.48 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $865.70 | 2019-2025 | |
| Abbvie INC. | $529.26 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $522.82 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.60 | 2019-2024 | Xifaxan |
| Esperion Therapeutics, INC. | $263.51 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $230.33 | 2020-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $186.80 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $172.56 | 2019-2023 | Verquvo, Lagevrio, Belsomra |
| Exact Sciences Corporation | $168.85 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Greco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.